Based on previous work that established fused heterocycles as viable alternatives for the picolinamide core of our lead series of mGlu5 negative allosteric modulators (NAMs), we designed a novel series of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide mGlu5 NAMs. These new quinoline derivatives also contained carbon linkers as replacements for the diaryl ether oxygen atom common to our previously published chemotypes. Compounds were evaluated in a cell-based functional mGlu5 assay, and an exemplar analog 27 was >60-fold selective versus the other seven mGlu receptors. Selected compounds were also studied in metabolic stability assays in rat and human S9 hepatic fractions and exhibited a mixture of P450- and non-P450-mediated metabolism.
|Number of pages||7|
|Journal||Bioorganic and Medicinal Chemistry Letters|
|State||Published - 1 Jun 2018|
- Central nervous system (CNS)
- G protein-coupled receptor (GPCR)
- Metabotropic glutamate receptor subtype 5 (mGlu)
- Negative allosteric modulator (NAM)